| Compound Information | SONAR Target prediction |
| Name: | Cinnarizine |
| Unique Identifier: | LOPAC 00778 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | C26H28N2 |
| Molecular Weight: | 340.292 g/mol |
| X log p: | 35.856 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 6.48 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 2 |
| Rotatable Bond Count: | 6 |
| Canonical Smiles: | C1CN(CCN1CC=Cc1ccccc1)C(c1ccccc1)c1ccccc1 |
| Class: | Ca2+ Channel |
| Action: | Blocker |
| Generic_name: | Cinnarizine |
| Chemical_iupac_name: | 1-benzhydryl-4-cinnamyl-piperazine |
| Drug_type: | Approved Drug |
| Kegg_compound_id: | C12725 |
| Drugbank_id: | APRD00332 |
| H2o_solubility: | 750 mg/L |
| Logp: | 5.63 |
| Cas_registry_number: | 298-57-7 |
| Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C298577&Index=0&Type=Mass&Large=on |
| Drug_category: | anti-emetics; antivertigo ATC:N07CA02 |
| Indication: | For the treatment of vertigo/meniere-s disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins. |
| Pharmacology: | Used in the treatment of motion sickness, vertigo and migraine. Cinnarizine is an antihistamine and a calcium channel blocker. Histamines mediate a number of activities such as contraction of smooth muscle of the airways and gastrointestinal tract, vasodilatation, cardiac stimulation, secretion of gastric acid, promotion of interleukin release and chemotaxis of eosinophils and mast cells. Competitive antagonists at histamine H1 receptors may be divided into first (sedating) and second (non-sedating) generation agents. Some, such as Cinnarizine also block muscarinic acetylcholine receptors and are used as anti-emetic agents. Cinnarizine through its calcium channel blocking ability also inhibits stimulation of the vestibular system. |
| Mechanism_of_action: | Binds to the Histamine H1 receptor and to muscarinic acetylcholine receptors. Cinnarizine also inhibits contractions of vascular smooth muscle cells by blocking L type calcium channels. Cinnarizine has also been implicated in binding to dopamine D2 receptors. |
| Organisms_affected: | Humans and other mammals |
| Found: 1 active | as graph: single | with analogs |
| Species: | 4932 |
| Condition: | MT2481-pdr1pdr3 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.6312±0.000707107 |
| Normalized OD Score: sc h | 0.9048±0.00180644 |
| Z-Score: | -5.3615±0.26111 |
| p-Value: | 0.000000127435 |
| Z-Factor: | 0.360917 |
| Fitness Defect: | 15.8757 |
| Bioactivity Statement: | Active |
| ps |
| DBLink | Rows returned: 5 |
| 2761 | 1-benzhydryl-4-cinnamyl-piperazine |
| 1547484 | 1-benzhydryl-4-cinnamyl-piperazine |
| 1615336 | 1-benzhydryl-4-cinnamyl-piperazine |
| 5553324 | 1-benzhydryl-4-cinnamyl-2,3,5,6-tetrahydropyrazine |
| 6444556 | 1-benzhydryl-4-cinnamyl-piperazine dihydrochloride |
| internal high similarity DBLink | Rows returned: 1 |
| SPE01500993 | 0.9024 |
| active | Cluster 3056 | Additional Members: 6 | Rows returned: 2 |
| SPE01500993 | 0 |
| LOPAC 00190 | 0 |
Service provided by the
Mike Tyers Laboratory